Caption Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-91,500
Closed -$11.7M – 2013
2022
Q1
$10.8M Buy
91,500
+71,500
+358% +$8.92M 0.13% 195
2021
Q4
$2.76M Sell
20,000
-64,700
-76% -$8.23M 0.03% 671
2021
Q3
$11.8M Buy
84,700
+76,200
+896% +$9.5M 0.13% 199
2021
Q2
$825K Sell
8,500
-4,100
-33% -$333K 0.01% 945
2021
Q1
$861K Sell
12,600
-242,006
-95% -$19.6M 0.02% 712
2020
Q4
$21.8M Buy
254,606
+121,606
+91% +$10.3M 0.5% 38
2020
Q3
$8.65M Buy
133,000
+77,684
+140% +$5.09M 0.2% 115
2020
Q2
$4.04M Buy
55,316
+33,464
+153% +$1.78M 0.13% 203
2020
Q1
$745K Sell
21,852
-147,148
-87% -$6.73M 0.04% 472
2019
Q4
$9.2M Sell
169,000
-99,900
-37% -$4.95M 0.31% 73
2019
Q3
$11.2M Buy
+268,900
New +$11.4M 0.58% 36
2019
Q2
– Sell
-123,400
Closed -$6.96M – 933
2019
Q1
$6.35M Buy
+123,400
New +$5.33M 0.35% 80

Other funds holding BHVN

Caption Management's BHVN Position: Q2 2022 in Review

Caption Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 91,500 shares — an estimated $11.7M sold.

Caption Management first reported a position in BHVN in Q1 2019 and held it in 12 quarters. The position peaked at $21.8M in Q4 2020. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

  • Caption Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
  • Caption Management sold 91,500 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $11.7M.
  • Caption Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 12 quarters.
  • Caption Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $21.8M in Q4 2020.
  • 329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Caption Management's 13F filing for Q2 2022, filed 15 Aug 2022.